Biomaterial Database

Antiandrogenic treatment for obsessive-compulsive disorder. 2000

T Eriksson

UI	MeSH Term	Description	Entries
D008297	Male		Males
D009771	Obsessive-Compulsive Disorder	An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.	Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000726	Androgen Antagonists	Compounds which inhibit or antagonize the biosynthesis or actions of androgens.	Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017329	Triptorelin Pamoate	A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	D-Trp-6-LH-RH,LHRH, Trp(6)-,Triptorelin,6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig),AY-25650,CL-118532,Decapeptyl,Decapeptyl Depot,Decapeptyl LP,Decapeptyl Trimestral,GnRH, Trp(6)-,LHRH, Tryptophyl(6)-,Trelstar,Triptorelin Embonate,Wy-42462,AY 25650,AY25650,CL 118532,CL118532,Embonate, Triptorelin,Pamoate, Triptorelin,Trimestral, Decapeptyl,Wy 42462,Wy42462
D017373	Cyproterone Acetate	An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.	Androcur,Cyproterone Acetate, (1 alpha,2 alpha)-Isomer,Cyproterone Acetate, (1 alpha,2 alpha,9 beta,10 alpha)-Isomer,Cyproterone Acetate, (17 alpha)-Isomer